Bookmark and Share
BioAssay: AID 463091

Late stage assay provider results from the probe development effort to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1): luminescence-based biochemical dose response assay to determine cytotoxicity of inhibitor compounds

Name: Late stage assay provider results from the probe development effort to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1): luminescence-based biochemical dose response assay to determine cytotoxicity of inhibitor compounds. ..more
_
   
 Tested Compounds
 Tested Compounds
All(4)
 
 
Unspecified(4)
 
 
 Tested Substances
 Tested Substances
All(4)
 
 
Unspecified(4)
 
 
 Related BioAssays
 Related BioAssays
AID: 463091
Data Source: The Scripps Research Institute Molecular Screening Center (HELACYTOX_INH_LUMI_384_4XCC50)
BioAssay Type: Panel, Confirmatory, Concentration-Response Relationship Observed
Depositor Category: NIH Molecular Libraries Probe Production Network, Assay Provider
BioAssay Version:
Deposit Date: 2010-08-09
Hold-until Date: 2011-06-09
Modify Date: 2011-06-10

Data Table ( Complete ):           All
Tested Compounds:
Depositor Specified Assays
Show more
AIDNameTypeProbeComment
2130Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).screening Primary screen (PME-1 inhibitors)
2143Summary of probe development efforts to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).summary3 Summary (PME-1 inhibitors)
2174Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).screening Counterscreen (LYPLA1 inhibitors)
2171Fluorescence polarization-based biochemical high throughput confirmation assay for inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).screening Confirmation assay (PME-1 inhibitors)
2177Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).screening Counterscreen (LYPLA2 inhibitors)
2232Counterscreen for PME1 inhibitors: fluorescence polarization-based biochemical high throughput confirmation assay to identify inhibitors of lysophospholipase 2 (LYPLA2).screening Counterscreen confirmation (LYPLA2 inhibitors)
2233Counterscreen for PME1 inhibitors: fluorescence polarization-based biochemical high throughput confirmation assay for inhibitors of lysophospholipase 1 (LYPLA1).screening Counterscreen confirmation (LYPLA1 inhibitors)
2291Fluorescence polarization-based Maybridge primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).screening Primary screen (PME-1 inhibitors, Maybridge Library)
2363Late stage results from the probe development effort to identify inhibitors of the protein methylesterase PME-1: Inhibition of PME-1-mediated demethylation of PP2ascreening MOA assay (Demethylation of PP2a)
2365Late stage results from the probe development effort to identify inhibitors of the protein methylesterase PME-1: Luminescence-based counterscreen assay to identify cytotoxic compoundsconfirmatory Counterscreen (cytotoxicity HEC 293T)
2366Late stage results from the probe development effort to identify inhibitors of the protein methylesterase PME-1: Gel-based Activity-Based Protein Profiling (ABPP) IC50confirmatory ABPP dose response screen (PME-1 inhibitors)
2368Late stage results from the probe development effort to identify inhibitors of the protein methylesterase PME-1: Gel-based Activity-Based Protein Profiling (ABPP) Gel Filtration Assayscreening MOA assay (PME-1 inhibitors gel filtration assay)
2369Late stage results from the probe development effort to identify inhibitors of the protein methylesterase PME-1: Gel-based Activity-Based Protein Profiling (ABPP) Inhibitionscreening ABPP screen (PME-1 inhibitors)
2371Late stage results from the probe development effort to identify inhibitors of the protein methylesterase PME-1: Gel-based Activity-Based Protein Profiling (ABPP) IC50: Purified enzymeconfirmatory ABPP dose response screen (PME-1 inhibitors, purified enzyme)
463124Late stage assay provider results from the probe development effort to identify inhibitors of protein phosphatase methylesterase 1 (PME-1): Gel-based Activity-Based Protein Profiling (ABPP) IC50 Set 2confirmatory
463130Late stage assay provider results from the probe development effort to identify inhibitors of protein phosphatase methylesterase 1 (PME-1): Gel-based Activity-Based Protein Profiling (ABPP) IC50 Set 1confirmatory
463131Late stage assay provider results from the probe development effort to identify inhibitors of protein phosphatase methylesterase 1 (PME-1): fluorescence-based cell-based inhibitionscreening
463132Late stage assay provider results from the probe development effort to identify inhibitors of protein phosphatase methylesterase 1 (PME-1): Inhibition of PME-1-mediated demethylation of PP2Ascreening
463146Late stage assay provider results from the probe development effort to identify inhibitors of protein phosphatase methylesterase 1 (PME-1): Fluorescence-based biochemical gel-based ABPPother
463149Late stage assay provider results from the probe development effort to identify inhibitors of PME-1: Fluorescence-based biochemical gel-based ABPP inhibition and selectivityother
588796Late stage assay provider results from the probe development effort to identify inhibitors of PME-1: fluorescence-based dose response biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of ABHD10 Set 2confirmatory
588801Late stage assay provider results from the probe development effort to identify inhibitors of PME-1: fluorescence-based dose response cell-based gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of ABHD10confirmatory
588802Late stage assay provider results from the probe development effort to identify inhibitors of PME-1: fluorescence-based dose response biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of ABHD10 Set 1confirmatory
588803Late stage assay provider results from the probe development effort to identify inhibitors of PME-1: LC-MS/MS-based cell-based ABPP-SILAC assayother1
588804Late stage assay provider results from the probe development effort to identify inhibitors of PME-1: absorbance-based cell-based dose response assay to determine cytotoxicity of inhibitor compoundsconfirmatory
588805Late stage assay provider results from the probe development effort to identify inhibitors of PME-1: ABHD10 inhibitor LC-MS/MS-based cell-based ABPP-SILAC assayother
588806Late stage assay provider results from the probe development effort to identify inhibitors of PME-1: fluorescence-based cell-based gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of ABHD10other
588807Late stage assay provider results from the probe development effort to identify inhibitors of PME-1: fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition and selectivity in a complex proteome for ABHD10other
588835Late stage assay provider results from the probe development effort to identify inhibitors of PME-1: fluorescence-based dose response cell-based gel-based competitive Activity-Based Protein Profiling (ABPP) ABHD10 selectivity assayother
602468Late stage assay provider results from the probe development effort to identify inhibitors of PME-1: fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition and selectivity among cysteine-reactive proteinsother
602485Late stage assay provider results from the probe development effort to identify inhibitors of PME-1: fluorescence-based cell-based gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of ABHD10 in vivoother
Description:
Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)
Center Affiliation: The Scripps Research Institute (TSRI)
Assay Provider: Benjamin Cravatt, TSRI
Network: Molecular Libraries Probe Production Centers Network (MLPCN)
Grant Proposal Number: 1 R01 CA132630-01
Grant Proposal PI: Benjamin Cravatt, TSRI
External Assay ID: HELACYTOX_INH_LUMI_384_4XCC50

Name: Late stage assay provider results from the probe development effort to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1): luminescence-based biochemical dose response assay to determine cytotoxicity of inhibitor compounds.

Description:

Reversible protein phosphorylation networks play essential roles in most cellular processes. While over 500 kinases catalyze protein phosphorylation, only two enzymes, PP1 and PP2A, are responsible for > 90% of all serine/ threonine phosphatase activity (1). Phosphatases, unlike kinases, achieve substrate specificity through complex subunit assembly and post-translational modifications rather than number. PP2A, for example, typically exists as heterotrimer with diverse subunits that may combinatorially make as many as 70 different holoenzyme assemblies (2). Mutations in several of these PP2A subunits have been identified in human cancers, suggesting that PP2A may act as a tumor suppressor (3). Adding further complexity, several residues of the catalytic subunit of PP2A can be reversibly phosphorylated, and the C-terminal leucine residue can be reversibly methylated (4,5). PME-1 is specifically responsible for demethylation of the carboxyl terminus (6).

Methylesterification is thought to control the binding of different subunits to PP2A, but little is known about physiological significance of this post-translational modification in vivo (7). Recently, PME-1 has been identified as a protector of sustained ERK pathway activity in malignant gliomas (8). In order to further elucidate the role of PP2A methylation in vivo, our lab has generated mice that lack PME-1 (PME-1 (-/-) mice) by targeted gene disruption (9). Unfortunately, PME-1 deletion resulted in perinatal lethality, underscoring the importance of PME-1 but hindering our biological studies. Biochemical elucidation of PME-1 would thus greatly benefit from the development of potent and selective chemical inhibitors.

References:

1. Oliver, C. J., Shenolikar, S. (1998). Physiologic importance of protein phosphatase inhibitors. Front. Biosci. 3, D961-972.
2. Janssens, V., Goris, J. (2001). Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem. J. 353, 417-439.
3. Janssens, V., Goris, J., Van Hoof, C. (2005). PP2A: the expected tumor suppressor. Curr. Opin. Genet. Dev. 15, 34-41.
4. Chen, J., Martin, B. L., Brautigan, D. L. (1992). Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation. Science 257, 1261-1264.
5. Favre, B., Zolnierowicz, S., Turowski, P., Hemmings, B. A. (1994). The catalytic subunit of protein phosphatase 2A is carboxyl-methylated in vivo. J. Biol. Chem. 269, 16311-16317.
6. Lee, J., Chen, Y., Tolstykh, T., Stock, J. (1996). A specific protein carboxyl methylesterase that demethylates phosphoprotein phosphatase 2A in bovine brain. Proc. Natl. Acad. Sci. U. S. A. 93, 6043-6047. PMID: 8650216.
7. Wu, J., Tolstykh, T., Lee, J., Boyd, K., Stock, J. B., Broach, J. R. (2000). Carboxyl methylation of the phosphoprotein phosphatase 2A catalytic subunit promotes its functional association with regulatory subunits in vivo. Embo J. 19, 5672-5681. PMID: 11060018.
8. Puustinen, P., Junttila, M. R., Vanhatupa, S., Sablina, A. A., Hector, M. E., Teittinen, K., Raheem, O., Ketola, K., Lin, S., Kast, J., Haapasalo, H., Hahn, W. C., Westermarck, J. (2009). PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant glioma. Cancer Res. 69, 2870-2877. PMID: 19293187.
9. Ortega-Gutierrez, S., Leung, D., Ficarro, S., Peters, E. C., Cravatt, B. F. (2008). Targeted disruption of the PME-1 gene causes loss of demethylated PP2A and perinatal lethality in mice. PLoS ONE 3, e2486. PMID: 18596935.

Keywords:

late stage, late stage AID, assay provider, powders, PME-1, protein phosphatase methylesterase 1, PPME-1, protein phosphatase 2a, PP2a, methylation, demethylation, lysophospholipase, LYPLA1, LYPLA2, tumor suppressor, cytotoxicity, viability, luminescence, dose response, counterscreen, Hela, inhibitor, cancer, Scripps, Scripps Research Institute Molecular Screening Center, SRIMSC, Molecular Libraries Probe Production Centers Network, MLPCN
Panel Information
Assays
PID§NameSubstancePanel TargetsDescription
ActiveInactive
1Serum-free Media4
2Fetal Calf Serum4

§ Panel component ID.
Protocol
Assay Overview:

The purpose of this assay is to determine cytotoxicity of inhibitor compounds belonging to aza-beta lactam scaffold. In this assay, HeLa cells in either serum-free media (Assay 1) or media containing FCS (Assay 2) are incubated with test compounds, followed by determination of cell viability. The assay utilizes the CellTiter-Glo luminescent reagent to measure intracellular ATP in viable cells. Luciferase present in the reagent catalyzes the oxidation of beetle luciferin to oxyluciferin and light in the presence of cellular ATP. Well luminescence is directly proportional to ATP levels and cell viability. As designed, compounds that reduce cell viability will reduce ATP levels, luciferin oxidation and light production, resulting in decreased well luminescence. Compounds were tested in quadruplicate in a 7-point 1:5 dilution series starting at a nominal test concentration of 50 uM.

Protocol Summary:

This assay was started by dispensing HeLa cells in RPMI media (15 uL, 5 x 10E3 cells/well) into a 384-well plate. Both serum-free media (Assay 1) and media supplemented with fetal calf serum (FCS) (Assay 2) were tested. Compound (5 uL of 0-200 uM in media containing 5% DMSO) was added to each well, giving final compound concentrations of 0-50 uM. Cells were incubated for 48hrs at 37 C in a humidified incubator and cell viability was determined by the CellTitre-Glo assay (Promega) according to manufacturer instructions.

The % cell viability for each well was then calculated as follows:

% Cell Viability = ( RFU_Test_Compound - MedianRFU_Low_Control ) / ( MedianRFU_High_Control - MedianRFU_Low_Control ) * 100

Where:

Test_Compound is defined as wells containing cells in the presence of test compound.
High_Control is defined as wells containing cells treated with media only (no compound).
Low_Control is defined as wells containing no cells (media only).

For each test compound, percent cell viability was plotted against the log of the compound concentration. The CC50 is reported as "> X uM" (where X = the highest concentration tested for which > 50% cell survival was observed).

PubChem Activity Outcome and Score:

Compounds with a CC50 value of less than 10 uM were considered active (cytotoxic). Compounds with a CC50 value greater than 10 uM were considered inactive (non-cytotoxic).

Any compound with a percent activity value > 50% at all test concentrations was assigned an activity score of zero. Any compound with a percent activity value < 50% at any test concentration was assigned an activity score greater than zero. Activity score was then ranked by the potency of the compounds with fitted curves, with the most potent compounds assigned the highest activity scores.

The PubChem Activity Score range for inactive compounds is 100-0. There are no active compounds.

List of Reagents:

HeLa cells (provided by Assay Provider)
RPMI Media (CellGro 10-040-CV)
FCS (Omega Scientific, FB-01)
Cell Titer-Glo (Promega, part G7572)
384-well plates (Corning 3704)
Comment
This assay was performed by the assay provider with powder samples of compounds. The results of our probe development efforts can be found at http://mlpcn.florida.scripps.edu/index.php/probes/probe-reports.html.
Result Definitions
Show more
TIDNameDescriptionPID§Panel TargetsHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
1Serum-free Media: OutcomeOne of Active, Inactive, or Not Tested1Outcome
2Serum-free Media: Score1Integer
3Serum-free Media: QualifierActivity Qualifier identifies if the resultant data CC50 came from a fitted curve or was determined manually to be less than or greater than its listed CC50 concentration.1String
4Serum-free Media: CC50*The value for concentration at which 50% of surviving cells are observed; CC50 shown in micromolar.1FloatμM
5Serum-free Media: Inhibition at 0.0032 uM [1] (0.0032μM**)Value of % Surviving cells at 0.0032 uM inhibitor concentration; replicate one.1Float%
6Serum-free Media: Inhibition at 0.0032 uM [2] (0.0032μM**)Value of % Surviving cells at 0.0032 uM inhibitor concentration; replicate two.1Float%
7Serum-free Media: Inhibition at 0.0032 uM [3] (0.0032μM**)Value of % Surviving cells at 0.0032 uM inhibitor concentration; replicate three.1Float%
8Serum-free Media: Inhibition at 0.0032 uM [4] (0.0032μM**)Value of % Surviving cells at 0.0032 uM inhibitor concentration; replicate four.1Float%
9Serum-free Media: Inhibition at 0.016 uM [1] (0.016μM**)Value of % Surviving cells at 0.016 uM inhibitor concentration; replicate one.1Float%
10Serum-free Media: Inhibition at 0.016 uM [2] (0.016μM**)Value of % Surviving cells at 0.016 uM inhibitor concentration; replicate two.1Float%
11Serum-free Media: Inhibition at 0.016 uM [3] (0.016μM**)Value of % Surviving cells at 0.016 uM inhibitor concentration; replicate three.1Float%
12Serum-free Media: Inhibition at 0.016 uM [4] (0.016μM**)Value of % Surviving cells at 0.016 uM inhibitor concentration; replicate four.1Float%
13Serum-free Media: Inhibition at 0.080 uM [1] (0.08μM**)Value of % Surviving cells at 0.080 uM inhibitor concentration; replicate one.1Float%
14Serum-free Media: Inhibition at 0.080 uM [2] (0.08μM**)Value of % Surviving cells at 0.080 uM inhibitor concentration; replicate two.1Float%
15Serum-free Media: Inhibition at 0.080 uM [3] (0.08μM**)Value of % Surviving cells at 0.080 uM inhibitor concentration; replicate three.1Float%
16Serum-free Media: Inhibition at 0.080 uM [4] (0.08μM**)Value of % Surviving cells at 0.080 uM inhibitor concentration; replicate four.1Float%
17Serum-free Media: Inhibition at 0.400 uM [1] (0.4μM**)Value of % Surviving cells at 0.400 uM inhibitor concentration; replicate one.1Float%
18Serum-free Media: Inhibition at 0.400 uM [2] (0.4μM**)Value of % Surviving cells at 0.400 uM inhibitor concentration; replicate two.1Float%
19Serum-free Media: Inhibition at 0.400 uM [3] (0.4μM**)Value of % Surviving cells at 0.400 uM inhibitor concentration; replicate three.1Float%
20Serum-free Media: Inhibition at 0.400 uM [4] (0.4μM**)Value of % Surviving cells at 0.400 uM inhibitor concentration; replicate four.1Float%
21Serum-free Media: Inhibition at 2 uM [1] (2μM**)Value of % Surviving cells at 2 uM inhibitor concentration; replicate one.1Float%
22Serum-free Media: Inhibition at 2 uM [2] (2μM**)Value of % Surviving cells at 2 uM inhibitor concentration; replicate two.1Float%
23Serum-free Media: Inhibition at 2 uM [3] (2μM**)Value of % Surviving cells at 2 uM inhibitor concentration; replicate three.1Float%
24Serum-free Media: Inhibition at 2 uM [4] (2μM**)Value of % Surviving cells at 2 uM inhibitor concentration; replicate four.1Float%
25Serum-free Media: Inhibition at 10 uM [1] (10μM**)Value of % Surviving cells at 10 uM inhibitor concentration; replicate one.1Float%
26Serum-free Media: Inhibition at 10 uM [2] (10μM**)Value of % Surviving cells at 10 uM inhibitor concentration; replicate two.1Float%
27Serum-free Media: Inhibition at 10 uM [3] (10μM**)Value of % Surviving cells at 10 uM inhibitor concentration; replicate three.1Float%
28Serum-free Media: Inhibition at 10 uM [4] (10μM**)Value of % Surviving cells at 10 uM inhibitor concentration; replicate four.1Float%
29Serum-free Media: Inhibition at 50 uM [1] (50μM**)Value of % Surviving cells at 50 uM inhibitor concentration; replicate one.1Float%
30Serum-free Media: Inhibition at 50 uM [2] (50μM**)Value of % Surviving cells at 50 uM inhibitor concentration; replicate two.1Float%
31Serum-free Media: Inhibition at 50 uM [3] (50μM**)Value of % Surviving cells at 50 uM inhibitor concentration; replicate three.1Float%
32Serum-free Media: Inhibition at 50 uM [4] (50μM**)Value of % Surviving cells at 50 uM inhibitor concentration; replicate four.1Float%
33Fetal Calf Serum: OutcomeOne of Active, Inactive, or Not Tested2Outcome
34Fetal Calf Serum: Score2Integer
35Fetal Calf Serum: QualifierActivity Qualifier identifies if the resultant data CC50 came from a fitted curve or was determined manually to be less than or greater than its listed CC50 concentration.2String
36Fetal Calf Serum: CC50*The value for concentration at which 50% of surviving cells are observed; CC50 shown in micromolar.2FloatμM
37Fetal Calf Serum: Inhibition at 0.0032 uM [1] (0.0032μM**)Value of % Surviving cells at 0.0032 uM inhibitor concentration; replicate one.2Float%
38Fetal Calf Serum: Inhibition at 0.0032 uM [2] (0.0032μM**)Value of % Surviving cells at 0.0032 uM inhibitor concentration; replicate two.2Float%
39Fetal Calf Serum: Inhibition at 0.0032 uM [3] (0.0032μM**)Value of % Surviving cells at 0.0032 uM inhibitor concentration; replicate three.2Float%
40Fetal Calf Serum: Inhibition at 0.0032 uM [4] (0.0032μM**)Value of % Surviving cells at 0.0032 uM inhibitor concentration; replicate four.2Float%
41Fetal Calf Serum: Inhibition at 0.016 uM [1] (0.016μM**)Value of % Surviving cells at 0.016 uM inhibitor concentration; replicate one.2Float%
42Fetal Calf Serum: Inhibition at 0.016 uM [2] (0.016μM**)Value of % Surviving cells at 0.016 uM inhibitor concentration; replicate two.2Float%
43Fetal Calf Serum: Inhibition at 0.016 uM [3] (0.016μM**)Value of % Surviving cells at 0.016 uM inhibitor concentration; replicate three.2Float%
44Fetal Calf Serum: Inhibition at 0.016 uM [4] (0.016μM**)Value of % Surviving cells at 0.016 uM inhibitor concentration; replicate four.2Float%
45Fetal Calf Serum: Inhibition at 0.080 uM [1] (0.08μM**)Value of % Surviving cells at 0.080 uM inhibitor concentration; replicate one.2Float%
46Fetal Calf Serum: Inhibition at 0.080 uM [2] (0.08μM**)Value of % Surviving cells at 0.080 uM inhibitor concentration; replicate two.2Float%
47Fetal Calf Serum: Inhibition at 0.080 uM [3] (0.08μM**)Value of % Surviving cells at 0.080 uM inhibitor concentration; replicate three.2Float%
48Fetal Calf Serum: Inhibition at 0.080 uM [4] (0.08μM**)Value of % Surviving cells at 0.080 uM inhibitor concentration; replicate four.2Float%
49Fetal Calf Serum: Inhibition at 0.400 uM [1] (0.4μM**)Value of % Surviving cells at 0.400 uM inhibitor concentration; replicate one.2Float%
50Fetal Calf Serum: Inhibition at 0.400 uM [2] (0.4μM**)Value of % Surviving cells at 0.400 uM inhibitor concentration; replicate two.2Float%
51Fetal Calf Serum: Inhibition at 0.400 uM [3] (0.4μM**)Value of % Surviving cells at 0.400 uM inhibitor concentration; replicate three.2Float%
52Fetal Calf Serum: Inhibition at 0.400 uM [4] (0.4μM**)Value of % Surviving cells at 0.400 uM inhibitor concentration; replicate four.2Float%
53Fetal Calf Serum: Inhibition at 2 uM [1] (2μM**)Value of % Surviving cells at 2 uM inhibitor concentration; replicate one.2Float%
54Fetal Calf Serum: Inhibition at 2 uM [2] (2μM**)Value of % Surviving cells at 2 uM inhibitor concentration; replicate two.2Float%
55Fetal Calf Serum: Inhibition at 2 uM [3] (2μM**)Value of % Surviving cells at 2 uM inhibitor concentration; replicate three.2Float%
56Fetal Calf Serum: Inhibition at 2 uM [4] (2μM**)Value of % Surviving cells at 2 uM inhibitor concentration; replicate four.2Float%
57Fetal Calf Serum: Inhibition at 10 uM [1] (10μM**)Value of % Surviving cells at 10 uM inhibitor concentration; replicate one.2Float%
58Fetal Calf Serum: Inhibition at 10 uM [2] (10μM**)Value of % Surviving cells at 10 uM inhibitor concentration; replicate two.2Float%
59Fetal Calf Serum: Inhibition at 10 uM [3] (10μM**)Value of % Surviving cells at 10 uM inhibitor concentration; replicate three.2Float%
60Fetal Calf Serum: Inhibition at 10 uM [4] (10μM**)Value of % Surviving cells at 10 uM inhibitor concentration; replicate four.2Float%
61Fetal Calf Serum: Inhibition at 50 uM [1] (50μM**)Value of % Surviving cells at 50 uM inhibitor concentration; replicate one.2Float%
62Fetal Calf Serum: Inhibition at 50 uM [2] (50μM**)Value of % Surviving cells at 50 uM inhibitor concentration; replicate two.2Float%
63Fetal Calf Serum: Inhibition at 50 uM [3] (50μM**)Value of % Surviving cells at 50 uM inhibitor concentration; replicate three.2Float%
64Fetal Calf Serum: Inhibition at 50 uM [4] (50μM**)Value of % Surviving cells at 50 uM inhibitor concentration; replicate four.2Float%

* Activity Concentration. ** Test Concentration. § Panel component ID.
Additional Information
Grant Number: 1 R01 CA132630-01

PageFrom: